Premium
Ewing's sarcoma
Author(s) -
Iyer Rajaram S.,
Rao S. R.,
Gurjal A.,
Nair Chandrika N.,
Pai Suresh K.,
Kurkure Purna A.,
Pande Subodh C.,
Advani Suresh H.
Publication year - 1993
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930520315
Subject(s) - medicine , vincristine , radiation therapy , sarcoma , surgery , cyclophosphamide , doxorubicin , ewing's sarcoma , chemotherapy , pathology
Abstract Between 1984–1987, 50 patients with Ewing's sarcoma of the bone were entered on combined modality protocol at Tata Memorial Hospital. Protocol treatment involved induction therapy consisting of 6‐week therapy with vincristine, Adriamycin (doxorubicin), and cyclophosphamide (VDC) followed by local radiotherapy 50 Gy to the involved bone. This was followed for six more cycles of VDC. Five patients had metastatic disease at presentation. Seventy‐six percent (38/50) of patients had disease either at axial or proximal site. With a median follow‐up of 48 months (range 14–87) 21 patients remained alive with disease‐free survival of 38.0% ± 2.5% at 5 years and overall survival of 36.0% ± 2.6% at 5 years. Twentyfive patients relapsed with five patients developing local failure and four local and distant metastasis. Using Lee‐Desu statistical methods, only response to therapy was a significant factor for survival. We conclude that more aggressive therapy with proper selection of local treatment modality including surgery and/or radiotherapy is required to produce more long‐term survival in high‐risk Ewing's sarcoma. © 1993 Wiley‐Liss, Inc.